Loading...
XERS
XNAS
Market cap3.10bUSD
Nov 20, Last price  
16.97USD
1D
2.11%
1Q
95.06%
IPO
-9.73%
Name

Xeris Biopharma Holdings Inc

Chart & performance

D1W1MN
XNAS:XERS chart
P/E
5,596.42
P/S
10.62
EPS
0.00
Vol. 1Y
55.53%
Shs. 5Y
32.29%
Rev. 5Y
70.20%
Div Yld LY
—
Div Yld TTM
—
Revenues
292m
+43.72%
1,075,0001,556,0002,465,0002,722,00020,435,00049,590,000110,248,000163,914,000203,070,000291,845,000
Net income
554k
P
-13,209,000-26,554,000-60,080,000-125,580,000-91,140,000-122,725,000-94,660,000-62,255,000-54,836,000554,000
CFO
29m
P
-16,087,000-24,663,000-56,279,000-80,558,000-80,558,000-95,535,000-102,891,000-47,023,000-36,981,00028,626,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

Key people

Marla Persky
Independent Chairman of the Board · since 2024
Kevin McCulloch
President, Chief Operating Officer · since 2024
John Shannon
Chief Executive Officer, Director · since 2024
Steven Pieper
Chief Financial Officer · since 2021
Anh Nguyen
Chief Medical Officer · since 2025
Chief Legal Officer, Corporate Secretary · since 2021
James Brady
Director · since 2025
BJ Bormann
Independent Director · since 2021
Dawn Halkuff
Independent Director · since 2021
John Johnson
Independent Director · since 2021
Garheng Kong
Independent Director · since 2021
Independent Director · since 2021
IPO date
Jun 21, 2018
Employees
355
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT